|

Creation of a Clinical Database on Primary Nervous System Tumors

RECRUITINGSponsored by Institut du Cancer de Montpellier - Val d'Aurelle
Actively Recruiting
SponsorInstitut du Cancer de Montpellier - Val d'Aurelle
Started2018-01-01
Est. completion2035-01
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

the creation of a clinical database including data for all PCNST patients is of high interest. This database will allow us to develop clinical studies on: * The clinical, radiological and biological presentation of tumors, the impact of oncological treatments and the evaluation of survival for the different subtypes of Primary central nervous system tumors (PCNST). This is particularly important for rare histological subtypes of PCNST for which the current knowledge is scarce; * Clinical, radiological and biological factors predictive of tumor response to treatments; * Prognostic factors.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adult patient aged ≥ 18, no age limit;
* Diagnosis of Primary central nervous system tumors ;
* Patient treated at the Montpellier Cancer Institute, whatever the treatment received (systemic treatment, radiotherapy or exclusive supportive care);
* For the retrospective part of the study, patient first treated at the Montpellier Cancer Institute between January 1rst, 2004 and the beginning of the prospective part;
* Patient information for the retrospective (patient still alive at the beginning of the study) and prospective study.

Exclusion Criteria:

* Secondary lesions of the central nervous system;
* Patient not affiliated to a social protection scheme;
* Subject under tutelage, curatorship or safeguard of justice.

Conditions2

CancerNervous System Tumor

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.